Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 74 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR How we are working with industry to translate research into real... April 26, 2022 Fine Needle Aspiration Biopsy: How to Prepare and What to Expect October 7, 2021 “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... November 25, 2020 Maintenance Therapy with CC-486 Extends Survival of Adults with AML January 16, 2020 Load more HOT NEWS Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin... Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma Scientists Link a Single Type of Bacteria to Colorectal Cancer
